Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA) surged 25.82% to $9.6 in the after-hours session following the reports that it has entered into a non-exclusive distribution agreement with Gabriel Science, LLC for the sale of Microcyn Technology products into the dental market and it has already taken its first order.
Sonoma manufactures Endocyn, a Microcyn Technology product, a biocompatible root canal irrigant that is non-staining for teeth or restorations. According to a study published in the Journal of Endodontics, Regenerative Endodontics by the Departments of Endodontics at Louisiana State University School of Dentistry, Endocyn showed less toxicity than sodium hypochlorite.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The full study can be found here: http://www.sciencedirect.com/science/article/abs/pii/S0099239917310439
Dr. Mark Fontenot, the managing member at Gabriel Science, LLC, said, “we believe Endocyn and the Microcyn family of products are the next generations of hypochlorous acid products that can assist in the treatment of a diverse range of dental, head and neck conditions.”
Amy Trombly, CEO of Sonoma Pharmaceuticals, said, “This is an exciting development in dental technology on our part, to expand our offerings of Microcyn-powered dental products available in the U.S. market.”